OTTAWA, ON — September 17, 2025 — Leads & Copy — DistillerSR has launched DistillerSR Agentic AI, combining expertly curated literature evidence with Agentic AI to provide research teams and business leaders with a validated, organization-wide source of evidence.
The new capability aims to improve decision-making and productivity in pharmaceutical and medical device companies, enabling faster and more cost-effective development and commercialization of new treatments. Unlike standalone large language models, DistillerSR Agentic AI ensures research accuracy by grounding outputs in peer-reviewed literature evidence, meeting high standards of reliability and reproducibility.
According to Peter O’Blenis, CEO of DistillerSR, this represents a leap forward in how life science organizations manage and act on evidence from literature reviews, providing a secure way to access expertly curated literature evidence across teams.
DistillerSR Agentic AI reduces the time and effort for research-intensive tasks, accelerating the drafting of regulatory reports and summarizing complex findings. The capability applies existing permission controls and copyright considerations, allowing validated data to be accessed company-wide.
DistillerSR has been applying AI to literature review workflows for over 15 years, with team member research cited in peer-reviewed publications more than 670 times. Recent innovations include Smart Evidence Extraction (SEE) and the adoption of the National Institute of Standards and Technology (NIST) AI RMF.
DistillerSR is trusted by global research organizations, including a majority of the largest pharmaceutical and medical device companies, contract research organizations, governments, NGOs, and academic institutions.
Vivian MacAdden, Director, Industry Stakeholder Programs, vivian.macadden@distillersr.com, (613) 212-0051
Source: DistillerSR
